Form 4 for ORMP ORAMED PHARMACEUTICALS INC.
Accepted 2022-08-01 00:00:00 ET · period of report 2022-07-28 · accession 0001209191-22-043766 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-01 | 2022-07-28 | ORMP | Sank Leonard | Dir | A - Grant | — | +12.0K | 18.0K | +200% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-28 | A | A | 12,000 | — | 18,000 | D | — | — | (F1) Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 4,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis. (F2) The reporting person previously reported and disclaimed beneficial ownership over 138,889 shares of common stock owned by a company wholly owned by a trust of which the reporting person was previously a trustee. The reporting person resigned as a trustee of such trust, effective February 3, 2022. |